
CAS 863971-19-1
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
6 produits concernés.
Mc-MMAF
CAS :Formule :C49H76N6O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :925.1613(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-Dihydro-1H-Pyrrol-1-Yl)-N-Methylhexanamido)-3-Methylbutanamido)-N,3-Dimethylbutanamido)-3-Methoxy-5-Methylheptanoyl)Pyrrolidin-2-Y
CAS :(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-Dihydro-1H-Pyrrol-1-Yl)-N-Methylhexanamido)-3-Methylbutanamido)-N,3-Dimethylbutanamido)-3-Methoxy-5-Methylheptanoyl)Pyrrolidin-2-YDegré de pureté :98%Masse moléculaire :925.16g/molMcMMAF
CAS :<p>McMMAF is a protective group-conjugated MMAF.</p>Formule :C49H76N6O11Degré de pureté :99.65% - >99.99%Couleur et forme :SolidMasse moléculaire :925.16MC-MMAF
CAS :<p>MC-MMAF is an antibody that binds to the epidermal growth factor receptor (EGFR) on tumor cells and inhibits the proliferation of tumor cells by blocking the binding of epidermal growth factor. MC-MMAF has been shown to be an effective treatment for a variety of cancers, including breast cancer, lung cancer, head and neck cancer, and colorectal cancer. It is also being studied as a potential treatment for autoimmune diseases such as rheumatoid arthritis and psoriasis. MC-MMAF has been shown to improve prognosis in patients with glomerular filtration rate (GFR) less than 30 mL/min per 1.73 m2.</p>Formule :C49H76N6O11Degré de pureté :Min. 95 Area-%Couleur et forme :White PowderMasse moléculaire :925.16 g/molMafodotin
CAS :Produit contrôlé<p>Applications Mafodotin is an anticancer immunoconjugate for the diagnosis and treatment of cancer or B Cell proliferative diseases.<br>References Valliere-Douglass, J.F., et al.: Anal. Chem., 84, 2843 (2012); Alley, S.C., et al.: Bioconjugate. Chem., 19, 759 (2008); Doronina, S.O., et al.: Bioconjugate. Chem., 17, 114 (2006);<br></p>Formule :C49H76N6O11Couleur et forme :NeatMasse moléculaire :925.1613




